Arrowhead Research | ARWR - Pre Tax Profit


Arrowhead Research reported $28.27M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
TG Therapeutics USD 20.36M 24.73M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026